Haemonetics Financials

HAE Stock  USD 88.53  0.07  0.08%   
Based on the key indicators related to Haemonetics' liquidity, profitability, solvency, and operating efficiency, Haemonetics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Haemonetics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 194.8 M, whereas Total Current Liabilities is forecasted to decline to about 161.5 M. Key indicators impacting Haemonetics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.340.8415
Way Down
Slightly volatile
Current Ratio1.352.5597
Way Down
Pretty Stable
The financial analysis of Haemonetics is a critical element in measuring its lifeblood. Investors should not minimize Haemonetics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Cash And Equivalents

214.13 Million

  
Understanding current and past Haemonetics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Haemonetics' financial statements are interrelated, with each one affecting the others. For example, an increase in Haemonetics' assets may result in an increase in income on the income statement.

Haemonetics Earnings Geography

Please note, the presentation of Haemonetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.

Haemonetics Stock Summary

Haemonetics competes with Merit Medical, AngioDynamics, AptarGroup, Envista Holdings, and Hologic. Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNew York Stock Exchange
ISINUS4050241003
CUSIP405024100
LocationMassachusetts; U.S.A
Business Address125 Summer Street,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.haemonetics.com
Phone781 848 7100
CurrencyUSD - US Dollar

Haemonetics Key Financial Ratios

Haemonetics Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets1.3B1.8B1.9B1.9B2.2B2.3B
Other Current Liab127.7M128.5M116.8M145.9M185.6M194.8M
Net Debt245.2M515.3M514.1M481.4M629.0M660.4M
Retained Earnings78.5M158.0M202.4M253.2M360.5M281.9M
Accounts Payable50.7M50.3M58.4M63.9M73.4M77.0M
Cash137.3M192.3M259.5M284.5M178.8M138.4M
Net Receivables165.2M127.6M159.4M179.1M206.6M120.7M
Inventory270.3M322.6M293.0M259.4M317.2M333.1M
Other Current Assets30.8M102.1M88.3M46.7M66.3M40.1M
Total Liab680.0M1.1B1.1B1.1B1.2B1.3B
Total Current Assets603.6M693.5M756.0M769.7M768.9M437.2M
Short Term Debt77.0M24.7M221.3M11.8M10.2M9.7M
Intangible Assets133.1M365.5M310.3M275.8M406.1M426.4M
Other Liab48.7M38.2M76.9M108.6M124.9M131.1M
Other Assets14.1M17.0M67.7M58.8M1.00.95
Long Term Debt305.5M690.6M559.4M754.1M797.6M837.4M
Good Will210.7M466.4M467.3M466.2M565.1M593.3M
Net Tangible Assets243.4M(100.3M)(28.1M)76.0M68.4M65.0M
Long Term Debt Total305.5M690.6M559.4M754.1M867.2M910.6M
Capital Surpluse553.2M602.7M572.5M594.7M683.9M516.6M

Haemonetics Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense16.2M16.8M17.1M14.6M13.0M15.4M
Total Revenue988.5M870.5M993.2M1.2B1.3B1.4B
Gross Profit484.5M397.8M505.5M615.1M691.5M726.1M
Operating Income154.0M58.0M80.8M156.0M164.9M173.1M
Ebit154.0M58.0M80.8M156.0M168.4M176.8M
Ebitda264.2M142.3M178.5M249.3M265.6M278.9M
Cost Of Revenue504.0M472.6M487.7M553.6M617.5M329.8M
Income Before Tax87.2M72.9M63.6M141.4M151.9M159.5M
Net Income76.5M79.5M43.4M115.4M117.6M123.4M
Income Tax Expense10.6M(6.6M)20.3M26.0M34.3M17.5M
Research Development30.9M32.9M46.8M50.1M54.4M33.3M
Tax Provision10.6M(6.6M)20.3M26.0M34.3M36.0M
Interest Income16.2M16.8M17.1M14.6M16.8M13.3M
Net Interest Income(16.2M)(16.8M)(17.1M)(14.6M)(13.0M)(13.7M)

Haemonetics Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory(84.7M)(38.9M)24.3M30.8M(60.1M)(57.1M)
Change In Cash(32.0M)55.0M67.2M25.0M(105.7M)(100.4M)
Free Cash Flow109.5M71.8M75.8M162.9M115.5M121.2M
Depreciation110.3M84.3M97.7M93.3M97.2M54.3M
Other Non Cash Items42.5M(919K)16.9M8.5M24.4M20.1M
Capital Expenditures48.8M37.0M96.5M110.2M66.3M54.3M
Net Income76.5M79.5M43.4M115.4M117.6M123.4M
End Period Cash Flow137.3M192.3M259.5M284.5M178.8M138.4M
Change To Netincome64.0M4.7M46.3M36.2M41.6M40.4M
Change Receivables18.9M44.1M(35.0M)(24.4M)(28.1M)(26.7M)
Net Borrowings31.9M370.7M(17.5M)269.3M309.6M325.1M
Investments(57.2M)(425.4M)(86.3M)(143.8M)(322.4M)(306.3M)

Haemonetics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Haemonetics's current stock value. Our valuation model uses many indicators to compare Haemonetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Haemonetics competition to find correlations between indicators driving Haemonetics's intrinsic value. More Info.
Haemonetics is rated # 3 in return on equity category among its peers. It is rated # 4 in return on asset category among its peers reporting about  0.42  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Haemonetics is roughly  2.38 . At present, Haemonetics' Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Haemonetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Haemonetics Systematic Risk

Haemonetics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Haemonetics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Haemonetics correlated with the market. If Beta is less than 0 Haemonetics generally moves in the opposite direction as compared to the market. If Haemonetics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Haemonetics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Haemonetics is generally in the same direction as the market. If Beta > 1 Haemonetics moves generally in the same direction as, but more than the movement of the benchmark.

Haemonetics Thematic Clasifications

Haemonetics is part of several thematic ideas from Baby Boomer Prospects to Obamacare Repeal. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Haemonetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Haemonetics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Haemonetics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.32)

At present, Haemonetics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Haemonetics November 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Haemonetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Haemonetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Haemonetics based on widely used predictive technical indicators. In general, we focus on analyzing Haemonetics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Haemonetics's daily price indicators and compare them against related drivers.

Complementary Tools for Haemonetics Stock analysis

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Commodity Directory
Find actively traded commodities issued by global exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges